{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:22:03Z","timestamp":1793672523436,"version":"4.5.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jad.2024.07.138","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T06:09:46Z","timestamp":1721455786000},"page":"542-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response"],"prefix":"10.1016","volume":"363","author":[{"given":"Svenja","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne B.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Tadic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Heilmann-Heimbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laven","family":"Mavarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f6rge","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie H.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Zillich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.07.138_bb0005","series-title":"MINI Plus: MINI International Neuropsychiatric Interview, Deutsche Version 5.0. 0","author":"Ackenheil","year":"1998"},{"key":"10.1016\/j.jad.2024.07.138_bb0010","series-title":"Practice Guideline for the Treatment of Patients With Major Depressive Disorder","author":"American Psychiatric Association (APA)","year":"2010"},{"key":"10.1016\/j.jad.2024.07.138_bb0015","first-page":"39","article-title":"Polygenic scores for psychiatric disease: from research tool to clinical application","volume":"32","author":"Andlauer","year":"2020","journal-title":"Med. Genet."},{"issue":"12","key":"10.1016\/j.jad.2024.07.138_bb0020","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/s41386-021-01097-0","article-title":"Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study","volume":"46","author":"Biernacka","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2024.07.138_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2024.07.138_bb0030","series-title":"Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)","author":"Bundes\u00e4rztekammer (B\u00c4K)","year":"2022"},{"key":"10.1016\/j.jad.2024.07.138_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115102","article-title":"Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis","volume":"321","author":"Bunka","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2024.07.138_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giz082","article-title":"PRSice-2: polygenic risk score software for biobank-scale data","volume":"8","author":"Choi","year":"2019","journal-title":"Gigascience"},{"key":"10.1016\/j.jad.2024.07.138_bb0045","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1176\/appi.focus.16407","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"16","author":"Cipriani","year":"2018","journal-title":"Focus"},{"issue":"10","key":"10.1016\/j.jad.2024.07.138_bb0050","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jad.2024.07.138_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004219","article-title":"MAGMA: generalized gene-set analysis of GWAS data","volume":"11","author":"de Leeuw","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jad.2024.07.138_bb0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12888-019-2014-x","article-title":"Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder","volume":"19","author":"Dreim\u00fcller","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/15622975.2021.2020334","article-title":"Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and response prediction: a post-hoc analysis from the early medication change trial in major depressive disorder","volume":"23","author":"Engelmann","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0070","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41398-022-02032-7","article-title":"Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial","volume":"12","author":"Engelmann","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2020.18.1.1","article-title":"Genetics of treatment outcomes in major depressive disorder: present and future","volume":"18","author":"Fabbri","year":"2020","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.jad.2024.07.138_bb0080","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.euroneuro.2018.05.009","article-title":"Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies","volume":"28","author":"Fabbri","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.07.138_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ijnp\/pyy024","article-title":"The genetics of treatment-resistant depression: a critical review and future perspectives","volume":"22","author":"Fabbri","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2024.07.138_bb0090","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41467-019-09718-5","article-title":"Polygenic prediction via Bayesian regression and continuous shrinkage priors","volume":"10","author":"Ge","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jad.2024.07.138_bb0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb5000","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpsychires.2021.05.048","article-title":"Early onset of depression and treatment outcome in patients with major depressive disorder","volume":"139","author":"Herzog","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2024.07.138_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2024.07.138_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(16)00143-4","article-title":"Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study","volume":"387","author":"Hou","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.07.138_bb0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","article-title":"Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions","volume":"22","author":"Howard","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jad.2024.07.138_bb0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpsychires.2016.03.016","article-title":"Combining clinical variables to optimize prediction of antidepressant treatment outcomes","volume":"78","author":"Iniesta","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2024.07.138_bb0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41398-022-02124-4","article-title":"Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study","volume":"12","author":"Islam","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0125","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.07.138_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/YCO.0000000000000377","article-title":"The potential of predictive analytics to provide clinical decision support in depression treatment planning","volume":"31","author":"Kessler","year":"2018","journal-title":"Curr. Opin. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2024.07.138_bb5005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.2009.10030434","article-title":"Linking molecules to mood: new insight into the biology of depression","volume":"167","author":"Krishnan","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0135","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41593-021-00860-2","article-title":"Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions","volume":"24","author":"Levey","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jad.2024.07.138_bb0140","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","article-title":"Polygenic risk scores: from research tools to clinical instruments","volume":"12","author":"Lewis","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.jad.2024.07.138_bb0145","first-page":"511","article-title":"BDNF plasma levels and BDNF exon IV promoter methylation as predictors for antidepressant treatment response","volume":"9","author":"Lieb","year":"2018","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2024.07.138_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.9758\/cpn.2021.19.1.12","article-title":"Biomarkers of major depressive disorder: knowing is half the battle","volume":"19","author":"Malik","year":"2021","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.jad.2024.07.138_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neuron.2019.03.022","article-title":"Uncovering the genetic architecture of major depression","volume":"102","author":"McIntosh","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.jad.2024.07.138_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2022.02.015","article-title":"The potential of polygenic risk scores to predict antidepressant treatment response in major depression: a systematic review","volume":"304","author":"Meerman","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.07.138_bb0165","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000529637","article-title":"Genomic investigation of remission and relapse of psychotic depression treated with sertraline plus olanzapine: the STOP-PD II study","volume":"82","author":"Men","year":"2023","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jad.2024.07.138_bb0170","series-title":"Depression in Adults: Treatment and Management","author":"National Institute for Health and Care Excellence (NICE)","year":"2022"},{"key":"10.1016\/j.jad.2024.07.138_bb0175","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41398-022-02221-4","article-title":"Polygenic heterogeneity in antidepressant treatment and placebo response","volume":"12","author":"N\u00f8hr","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bpsgos.2021.07.008","article-title":"Identifying the common genetic basis of antidepressant response","volume":"2","author":"Pain","year":"2022","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/j.jad.2024.07.138_bb0185","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00390-6","article-title":"Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.07.138_bb0190","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jad.2024.07.138_bb0195","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1067\/mhj.2002.123579","volume":"144","author":"Schmermund","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jad.2024.07.138_bb0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00406-016-0741-2","article-title":"Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies","volume":"267","author":"Spellmann","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2024.07.138_bb0205","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1176\/appi.ajp.157.10.1552","article-title":"Genetic epidemiology of major depression: review and meta-analysis","volume":"157","author":"Sullivan","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.07.138_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-11-21","article-title":"Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder\u2014the EMC trial","volume":"11","author":"Tadi\u0107","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.jad.2024.07.138_bb0215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.euroneuro.2016.02.003","article-title":"Randomized controlled study of early medica- tion change for non-improvers to antidepressant therapy in major depression\u2014the EMC trial","volume":"26","author":"Tadi\u0107","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.07.138_bb0220","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jad.2024.07.138_bb0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000318162","article-title":"Standardized rater training for the Hamilton Depression Rating Scale (HAMD(17)) and the Inventory of Depressive Symptoms (IDS (C30))","volume":"44","author":"Wagner","year":"2011","journal-title":"Psychopathology"},{"key":"10.1016\/j.jad.2024.07.138_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203896","article-title":"Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: meta-analysis of three treatment cohorts","volume":"13","author":"Ward","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2024.07.138_bb0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41397-019-0067-3","article-title":"Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP","volume":"20","author":"Wigmore","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.jad.2024.07.138_bb0240","series-title":"Skid. Strukturiertes klinisches Interview f\u00fcr DSM-IV. Achse I und II. Handanweisung","author":"Wittchen","year":"1997"},{"key":"10.1016\/j.jad.2024.07.138_bb0245","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41588-018-0090-3","article-title":"Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression","volume":"50","author":"Wray","year":"2018","journal-title":"Nat. Genet."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724011960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724011960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T23:07:29Z","timestamp":1725145649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724011960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":51,"alternative-id":["S0165032724011960"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.138","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}